5:30 PM
 | 
Mar 14, 2013
 |  BC Extra  |  Clinical News

Sinovac vaccine meets primary in Phase III trial

Sinovac Biotech Ltd. (NASDAQ:SVA) said its vaccine against human enterovirus 71 (EV71) met the primary endpoint of preventing hand, foot and mouth disease (HFMD) caused by EV71 vs. placebo...

Read the full 126 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >